The enhancement of Lantern Pharma's RADR platform is directly related to the company's core business of drug development. This improvement could potentially lead to more efficient and effective development processes, which could in turn lead to faster approvals and market entry of their drugs. This could positively impact the company's revenues and profitability in the future, thus potentially leading to a positive impact on the company's stock price.